Pharmaceuticals

Myelodysplastic Syndrome (MDS) Drugs Market Revenue Projected To Hit $10.25 Billion By 2030 With 8.3% CAGR

May 1, 2026May 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Myelodysplastic Syndrome (MDS) Drugs Market Grow Between 2026 And 2030?

The myelodysplastic syndrome (mds) drugs market has experienced robust expansion recently. This market is projected to expand from $3.7 billion in 2025 to $3.98 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 7.6%. Historically, this growth was driven by factors such as a rise in bone marrow disorder diagnoses, the widespread availability of hypomethylating agents, the proliferation of oncology treatment facilities, the increased application of supportive transfusion therapies, and heightened awareness of the disease.

The myelodysplastic syndrome (MDS) drugs market size is anticipated to undergo significant expansion in the coming years. It is projected to attain $5.56 billion by 2030, progressing at a compound annual growth rate (CAGR) of 8.7%. The market’s growth throughout the forecast period stems from the increasing development of novel immunomodulatory drugs, rising adoption of precision medicine in hematology, expansion of clinical trial pipelines, growing focus on improving patient quality of life, and increasing healthcare spending on rare diseases. Prominent patterns expected in this period encompass the increasing use of targeted therapeutic regimens, rising adoption of oral and parenteral combination therapies, growing focus on personalized treatment approaches, expansion of supportive care therapies, and enhanced monitoring of treatment outcomes.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13043&type=smp

Which Key Drivers Are Affecting The Myelodysplastic Syndrome (MDS) Drugs Market Development?

The anticipated rise in myeloid leukemia cases is projected to fuel expansion within the myelodysplastic syndrome (MDS) drug treatment market. Myeloid leukemia, a form of cancer, originates in the bone marrow and impacts cells vital for producing various blood cell types. Myelodysplastic syndrome (MDS) drugs are designed to enhance bone marrow function by addressing the underlying cause of leukemia, thereby minimizing the risk of complications from low blood cell counts, decreasing the necessity for chemotherapy and transplants, and boosting survival rates for individuals with myelodysplastic syndrome (MDS). For example, estimates from the American Cancer Society, a US-based voluntary health organization, indicated that in January 2023, approximately 20,380 cases and 11,310 deaths from acute myeloid leukemia (AML) were expected among adults in 2023. Consequently, the rising prevalence of myeloid leukemia is a key driver for the myelodysplastic syndrome (MDS) drug market.

How Is The Myelodysplastic Syndrome (MDS) Drugs Market Categorized Across Its Segment Groups?

The myelodysplastic syndrome (mds) drugs market covered in this report is segmented –

1) By Drug Type: Chemotherapy, Immunomodulatory Drugs

2) By Route Of Administration: Oral, Parenteral

3) By Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts

4) By End User: Hospitals, Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Chemotherapy: Hypomethylating Agents, Cytotoxic Agents

2) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide

Which Trends Are Guiding The Direction Of The Myelodysplastic Syndrome (MDS) Drugs Market?

Leading companies in the myelodysplastic syndrome (MDS) drugs market are concentrating on developing novel products, such as targeted therapy, to enhance patient outcomes, fulfill specific customer needs, and integrate effectively into the healthcare ecosystem. This targeted therapy for myelodysplastic syndromes (MDS) involves the use of medications specifically designed to pinpoint and address genetic mutations or molecular irregularities in cancer cells, aiming to improve results by selectively attacking abnormal cells while minimizing harm to healthy tissue. For example, in October 2023, the U.S. Food and Drug Administration (FDA) sanctioned Tibsovo (ivosidenib) for treating adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) who possess an isocitrate dehydrogenase-1 (IDH1) mutation. The effectiveness of Tibsovo for this particular new use was examined in an open-label, single-arm, multicenter study that included 18 adult patients suffering from relapsed or refractory MDS with an IDH1 mutation.

Which Firms Are Influencing Competition In The Myelodysplastic Syndrome (MDS) Drugs Market?

Major companies operating in the myelodysplastic syndrome (mds) drugs market are Bristol Myers Squibb, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma Inc., Aprea Therapeutics, Onconova Therapeutics Inc., Geron Corporation, Amgen Inc., Sandoz, Gilead Sciences Inc., Johnson And Johnson, Lupin Ltd. Corporation, Ono Pharmaceutical Co. Ltd., Eisai Co. Ltd., Nippon Shinyaku Co. Ltd., Lupin Ltd., Accord Healthcare Inc., Kite Pharma Inc., Karyopharm Therapeutics Inc., Aprea Therapeutics Inc., Acceleron Pharma Inc., Astex Pharmaceuticals Inc., Stemline Therapeutics Inc., Geron Corporation, Onconova Therapeutics Inc., Actinium Pharmaceuticals Inc., Millennium Pharmaceuticals Inc.

Get The Full Myelodysplastic Syndrome (MDS) Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-mds-drugs-global-market-report

Which Region Holds The Highest Market Share In The Myelodysplastic Syndrome (MDS) Drugs Market?

North America was the largest region in the myelodysplastic syndrome (MDS) drugs market in 2025. The regions covered in the myelodysplastic syndrome (mds) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Myelodysplastic Syndrome (MDS) Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-mds-drugs-global-market-report

Browse Through More Reports Similar to the Global Myelodysplastic Syndrome (MDS) Drugs Market 2026, By The Business Research Company

Bone Marrow Transplantation Market Report 2026

https://www.thebusinessresearchcompany.com/report/bone-marrow-transplantation-global-market-report

Blood Transfusion Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/blood-transfusion-diagnostics-global-market-report

Patient Blood Management Market Report 2026

https://www.thebusinessresearchcompany.com/report/patient-blood-management-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795